EUVIMEDEUVIMED entdecken
FallberichtLeserbrief

Successful treatment of aggressive metastatic sebaceous carcinoma with pembrolizumab

Narumi Jikihara, Kazunori Yokoi, Yutaka Matsumura, Yosuke Ishitsuka, Eiji Kiyohara, Rei Watanabe, Satoshi Nojima, Eiichi Morii, Masateru Fujiwara, Manabu Fujimoto, Atsushi Tanemura

European Journal of Dermatology · 2024

DOI: 10.1684/ejd.2024.4697 ↗

Kurz gefasst

Fallbericht in der Zeitschrift European Journal of Dermatology, 2024. Verfasst von Narumi Jikihara und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Osaka University Graduate School of Medicine, Suita, Osaka, Japan. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Sebaceous Gland Neoplasms, Antineoplastic Agents, Immunological. Die Arbeit wurde bisher 2-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BackgroundPalmoplantar keratoderma (PPK) is a group of ­disorders with genetic and phenotypic heterogeneity featuring skin thickening of the palms and soles. More than 60 genes involved in various biological processes are implicated in PPK. PIK3CA is an oncogene encoding p110α, and its somatic variants contribute to a spectrum of congenital overgrowth disorders, including epidermal nevi (EN).ObjectivesTo identify the genetic basis and elucidate the pathogenesis of a patient with unilateral focal PPK.Materials & MethodsWhole-exome sequencing and Sanger sequencing combined with laser capture microdissection (LCM) were performed on genomic DNA extracted from the patient’s peripheral blood and skin lesion. Skin biopsies were taken from the lesion of the patient and normal controls for immunofluorescence. Molecular docking was performed using Alphafold2-multimer.ResultsA three-year-old girl presented with unilateral focal PPK with an identified missense ­variant (c.3140A>G, p.His1047Arg) in PIK3CA from affected tissue. This variant only existed in the lesional epidermis. Elevated PI3K/AKT/mTOR signalling in the affected epidermis and an increased number of Ki67-positive keratinocytes were demonstrated. Molecular docking indicated instability of the p110α-p85α dimer caused by the PIK3CA His1047Arg variant.ConclusionWe describe the first PPK case associated with a variant in PIK3CA, which expands the spectrum of PIK3CA-related disorders. Our study further underscores the importance of the PI3K/AKT/mTOR pathway in the homeostasis of skin keratinization.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedSebaceous Gland NeoplasmsAntineoplastic Agents, ImmunologicalHumansMaleAdenocarcinoma, SebaceousAgedFemale

Substanzen

pembrolizumabAntibodies, Monoclonal, HumanizedAntineoplastic Agents, Immunological

Autor:innen und Institutionen

  • Department of Dermatology, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.
  • Department of Pathology, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.
  • Department of Radiation Oncology, Suita Tokusyukai Hospital, Suita, Osaka, Japan.

Zitieren

APA

Jikihara, N., Yokoi, K., Matsumura, Y., Ishitsuka, Y., Kiyohara, E., Watanabe, R., Nojima, S., Morii, E., Fujiwara, M., Fujimoto, M., & Tanemura, A. (2024). Successful treatment of aggressive metastatic sebaceous carcinoma with pembrolizumab. European Journal of Dermatology. https://doi.org/10.1684/ejd.2024.4697

Vancouver

Jikihara N, Yokoi K, Matsumura Y, Ishitsuka Y, Kiyohara E, Watanabe R, et al. Successful treatment of aggressive metastatic sebaceous carcinoma with pembrolizumab. European Journal of Dermatology. 2024. doi:10.1684/ejd.2024.4697

BibTeX
@article{Jikihara2024,
  author = {Jikihara, Narumi and Yokoi, Kazunori and Matsumura, Yutaka and Ishitsuka, Yosuke and Kiyohara, Eiji and Watanabe, Rei and Nojima, Satoshi and Morii, Eiichi and Fujiwara, Masateru and Fujimoto, Manabu and Tanemura, Atsushi},
  title = {Successful treatment of aggressive metastatic sebaceous carcinoma with pembrolizumab},
  journal = {European Journal of Dermatology},
  year = {2024},
  doi = {10.1684/ejd.2024.4697}
}
Kostenlos starten →